BiotechTube

AK102 + Statins + Ezetimibe

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Homozygous Familial Hypercholesterolemia

Conditions

Homozygous Familial Hypercholesterolemia

Trial Timeline

May 13, 2019 → Mar 15, 2021

NCT ID
NCT03933293

About AK102 + Statins + Ezetimibe

AK102 + Statins + Ezetimibe is a phase 2 stage product being developed by Akeso for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03933293. Target conditions include Homozygous Familial Hypercholesterolemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03933293Phase 2Completed

Competing Products

20 competing products in Homozygous Familial Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
77
Rosuvastatin 20mgAstraZenecaPhase 3
77
Inclisiran + PlaceboNovartisPhase 3
77
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
77
InclisiranNovartisPhase 3
77
INC280 + BuparlisibNovartisPhase 1/2
41
Inclisiran + PlaceboNovartisPhase 3
77
Evolocumab + PlaceboAmgenPhase 2/3
64
evolocumabAmgenApproved
84
MBX-8025 50 mg (Dose Escalation Period 1) + MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) + MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)Gilead SciencesPhase 2
51
IBI306 + IBI306Innovent BiologicsPhase 2/3
64
BMS-986504 + [14C]-BMS-986504Bristol Myers SquibbPhase 1
32
Lumacaftor Plus Ivacaftor Combination + Ivacaftor + PlaceboVertex PharmaceuticalsPhase 3
76
Placebo + Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
76
Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
76
Alirocumab + PlaceboSanofiPhase 3
76
EvinacumabRegeneron PharmaceuticalsPhase 3
76
evinacumabRegeneron PharmaceuticalsPhase 3
76
REGN1500 250 mg SC/15 mg/kg IV/450 mg SCRegeneron PharmaceuticalsPhase 2
51
EvinacumabRegeneron PharmaceuticalsPre-clinical
22

Other Products from Akeso

AK104(SC) + AK104(IV) + Capecitabine + Oxaliplatin injectionPhase 3
76
AK111 + AK111 + PlaceboPhase 3
76
AK104 + LenvatinibPhase 3
76
Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium FolinatePhase 3
76
AK102 + AK102 + Placebo + PlaceboPhase 3
76